News

The FDA has approved a 0.15mg dosage of Symjepi, an epinephrine injection, for the emergency treatment of serious allergic reactions in children.

Robert J. Kreitman, MD, discusses the FDA’s recent approval of moxetumomab pasudotox (Lumoxiti) for the treatment of hairy cell leukemia (HCL).

Less than one-third received both influnza and Tdap vaccination during their pregnancies, citing limited understanding or assurance of their benefits and safety.

The FDA has granted an orphan drug designation to Q Therapeutics Inc.’s Q-Cell for the treatment of transverse myelitis.

The FDA recognized the potential of proCase, which is being developed to treat blood clots and does not increase the risk of bleeding.

How can caregivers improve their management of treatments—both in cost and in availability—for children in need of help due to asthma.

A modeling analysis suggests state officials in Indiana could have prevented upwards of 95% of the HIV cases in a 2014 outbreak.

In response to the evidenced connection between pediatric asthma development and air pollution exposure, investigators have sought out association indicators as early as in utero.

Patients who acquired C difficile infection while in the hospital were more than twice as likely to be discharged somewhere other than home, such as to a nursing home or long-term care facility.

The US FDA has granted an orphan drug designation to Cellectar Biosciences, Inc.’s CLR 131 for the treatment of pediatric osteosarcoma.

Investigators will assess the efficacy, safety, and tolerability of NanoFlu doses and formulations—both adjuvanted and unadjuvanted—in comparison to a pair of US marketed vaccines.

Of patients with a baseline blood eosinophil count of 300 cells per mL or more who were given benralizumab every 8 weeks, 75% were exacerbation-free during their second year of treatment.

A recent study investigating the HSPG2 gene in connection with tardive dyskinesia sheds new light on the root causes of the condition.

The findings lend to investigators believe that earlier endpoints for AMD diagnosis are needed.

When expectant mothers started antiretroviral therapy before pregnancy, their HIV-exposed but uninfected infants had lower infection risk than infants whose mothers started ART during pregnancy.

Electronic medical records alerts about patients at risk for C difficile infection seemed to increase the incidence, but investigators pointed toward improved detection as the culprit.

Pediatric traumatic brain injuries were found to be associated with a variety of health conditions and states with greater levels of private insurance and insurance adequacy.

The FDA has granted an orphan drug designation to Myelo Therapeutics GmbH’s Myelo001 for the treatment of acute radiation syndrome.

In animal models, not only did the drug help protect apelin function-deficient models from laser-induced choroidal neovascularization, but it did it through unique mechanisms that were independent of VEGF function.

The FDA has approved duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 prior therapies and adult patients with relapsed or refractory follicular lymphoma after at least 2 prior systemic therapies.

Investigators have found that the higher the symptom burden, the greater the detrimental impact on work productivity and daily activity for patients with myeloproliferative neoplasms.

The PrEPmate support intervention increased visit attendance and PrEP adherence among young men who have sex with men.

Female sex, previous gastrointestinal, and non-gastrointestinal comorbidities are associated with C difficile infection in women with UTIs, study finds.

The Eluvia stent system was approved based on data from the IMPERIAL non-inferiority trial, which compared Eluvia to Zilver PTX.

A comparative study found that online prevention programs are just as effective and have higher participation rates compared to in-person programs.

Tumor regressions were observed in 2 of the first 4 evaluable patients in the ongoing phase 2 trial evaluating DPX-Survivac in combination with low dose cyclophosphamide and pembrolizumab.

Pivotal clinical trial costs increased if more patients were needed to document treatment benefit, if active drug comparators were used, or to measure clinical end points rather than a change in a surrogate outcome.

The capsules of icosapent ethyl, which is derived from fish, showed a 25% relative risk reduction compared to placebo.